ClinicalTrials.Veeva

Menu

Pulsed Field Ablation With Concomitant Radiofrequency Cardioneuroablation in Patients With Paroxysmal Atrial Fibrillation (PFACNA-AF)

S

St. Joseph's Centre, Poland

Status

Enrolling

Conditions

Atrial Fibrillation (Paroxysmal)

Treatments

Procedure: Pulmonary Vein Isolation using Point-by-Point Bipolar Pulsed-Field Ablation
Procedure: Selective Radiofrequency Ablation of the Superior Paraseptal Parasympathetic Ganglion

Study type

Interventional

Funder types

Other

Identifiers

NCT07171463
12/2025/B

Details and patient eligibility

About

Pulsed-field ablation (PFA) is a novel, non-thermal method for the treatment of atrial fibrillation (AF). It uses short, high-voltage electrical pulses to selectively ablate cardiomyocytes. PFA has demonstrated a high safety profile with reduced complication rates compared to thermal ablation.

Thermal ablation of parasympathetic ganglia during conventional pulmonary vein isolation (PVI) may improve long-term procedural outcomes by reducing AF recurrence. However, due to its non-thermal nature, PFA may not significantly affect cardiac autonomic innervation, which could be clinically relevant in vagally mediated AF or tachycardia-bradycardia syndrome.

This randomized study compares two strategies: (1) PFA-only PVI, and (2) PFA combined with selective thermal ablation (radiofrequency energy) of the superior paraseptal parasympathetic ganglion. The primary objective is to evaluate whether adjunctive thermal ablation improves clinical outcomes and reduces intraprocedural bradyarrhythmic events.

Enrollment

20 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥18 years
  • Documented paroxysmal atrial fibrillation (AF) lasting ≥30 seconds on ECG or Holter monitoring
  • Willingness and ability to provide written informed consent
  • Life expectancy >1 year

Exclusion criteria

  • Persistent AF lasting >7 days or long-standing AF >1 year
  • Secondary AF due to electrolyte imbalance, thyroid disease, alcohol abuse, or other non-cardiac causes
  • Left atrial anteroposterior diameter ≥45 mm on transthoracic echocardiography
  • Clinically significant coexisting arrhythmias other than AF
  • Significant valvular heart disease or valve prosthesis
  • Chronic heart failure NYHA class III/IV
  • Previous AF or atrial flutter ablation
  • Prior closure of atrial septal defect or left atrial appendage
  • Atrial myxoma
  • Implanted pacemaker or defibrillator
  • History of pericarditis
  • Congenital heart disease
  • Coagulopathy or bleeding disorders
  • Contraindications to oral anticoagulation
  • Contraindications to CT or MRI
  • Pregnancy or breastfeeding
  • Body Mass Index >30
  • History of organ transplantation
  • Severe pulmonary disease
  • Estimated Glomerular Filtration Rate <30 mL/min/1.73 m²
  • Active malignancy
  • Significant infection
  • Life expectancy <1 year
  • Psychiatric disorders preventing study participation
  • Refusal or inability to provide informed consent

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

20 participants in 2 patient groups

PFA with selective thermal ganglion ablation
Experimental group
Description:
Participants will undergo pulmonary vein isolation using a point-by-point bipolar pulsed-field ablation. In addition, selective thermal ablation using radiofrequency energy will be performed at the anterior aspect of the right superior pulmonary vein, corresponding to the anatomical region of the superior paraseptal parasympathetic ganglion.
Treatment:
Procedure: Selective Radiofrequency Ablation of the Superior Paraseptal Parasympathetic Ganglion
Procedure: Pulmonary Vein Isolation using Point-by-Point Bipolar Pulsed-Field Ablation
Standard PFA pulmonary vein isolation
Active Comparator group
Description:
Participants will undergo pulmonary vein isolation using the same point-by-point bipolar PFA system without any additional thermal applications.
Treatment:
Procedure: Pulmonary Vein Isolation using Point-by-Point Bipolar Pulsed-Field Ablation

Trial contacts and locations

1

Loading...

Central trial contact

Łukasz Zarębski, MD; Piotr Futyma, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems